Background: Bicuspid aortic valve (BAV) stenosis has been considered a relative
have severe aortic stenosis (AS). However, high-risk patients with congenital bicuspid aortic valve (BAV) stenosis were excluded from initial randomized trials and registries due to anatomical and technical challenges. 1, 2 Patients with BAV have altered aortic geometry and blood flow; variable coronary artery anatomy; larger annular dimensions; and more calcified, bulky, and irregular leaflets. 3, 4 These differences can complicate accurate delivery and complete apposition of the prosthetic valve, 5 raising concerns about higher rates of paravalvular leak (PVL), postprocedural complications, and worse outcomes. [5] [6] [7] Although BAV is the most common congenital heart disease involving 1% of the population, 8, 9 TAVR outcomes were not adequately investigated in patients with BAV. Initial studies hypothesized that TAVR can be a possible option for high-risk patients with BAV stenosis, but outcomes of TAVR with early-generation valves were less than satisfactory. 10, 11 Later reports using new generation valves showed promising results with less PVL and fewer postprocedural complications. [12] [13] [14] [15] [16] There are limited data regarding outcomes of TAVR in patients with BAV and the majority of these studies have not considered a control group of patients with trileaflet aortic valve stenosis. 12 Patients with BAV tend to develop symptomatic AS at a younger age. The application of TAVR technology has now been expanded to intermediate-risk patients, and potentially low-risk patients in the future. Therefore, a larger pool of patients with BAV will be considered for TAVR. 17 Thus, we designed this single center cohort study to investigate outcomes of TAVR in patients with BAV stenosis. 3 | RESULTS
| METHODS AND MATERIALS

| Patients demographics
Thirty-two patients in the BAV group and 96 patients in the TAV group were included. Twenty (62.5%) patients in the BAV group and 54 (56.2%) patients in the TAV group were male. Mean ± SD age of patients in the BAV group was lower than those in the TAV group, 68.59 ± 11.07 versus 73.96 ± 10.76 (P = 0.04). The BAV group had a similar mean ± SD STS risk score to the TAV group, 6.01 ± 3.42 versus 6.08 ± 3.76 (P = 0.92 ) (P = 0.048). Mean ± SD sinus of Valsalva diameter was 35.7 ± 4 mm in the BAV group and it was 31.2 ± 2.3 in the TAV group (P = 0.012). Baseline characteristics between the two groups are summarized in Table 1 . Based on Sievers classification for BAV patients, 24 (75%) patients had type 0, four (12.5%) patients had type 1, and two (6.25%) patients had type 2 BAV. In two (6.25%) patients, the classification remained unknown because they were referred from outside hospitals with archived CT imaging that was not accessible.
| Periprocedural and 30-day outcomes
The majority of patients underwent TAVR via a TF approach, 27 (84.37%) patients in the BAV group and 69 (71.87%) patients in the Table 2) . Overall mean ± SD valve oversize by area was 4.3 ± 15.3% for balloon-expandable valves, which was not significantly different between the BAV and TAV groups, 6.6 ± 17.5% versus 3.6 ± 14.7
(P = 0.51), respectively. For self-expandable valves, total mean ± SD valve oversize by perimeter was −3.5 ± 10.4 which was similar between the two groups: −3.53 ± 11.4 in the BAV group and −3.44 ± 9.6 in the TAV group (P = 0.99), although the number of patients who underwent TAVR with a self-expandable valve was not enough to draw a clinical conclusion ( Table 2) .
TAVR was successfully performed in 100% of patients. No intraoperative death, annulus rupture, or aortic dissection was detected in either group. Following TAVR, two (6.25%) patients in the BAV group (due to stroke and sudden cardiac arrest) and two (2.08%) patients in the TAV group (stroke and respiratory failure) died during the hospitalization (P = 0.09). Thirty-day mortality rate was 4.16% (n = 4) in TAV group versus 6.25% (n = 2) in the BAV group (P = 0.63). Postoperative stroke was detected in two (6.25%) patients in the BAV group and three (3.12%) patients in the TAV group (P = 0.59). Four (12.5%) patients in the BAV group and 13 (13.54%) patients in the TAV group required pacemaker implantation (P = 0.1).
No patient required reoperation in either group. There were six patients, two (6.25%) patients in the BAV group and four (4.1%) patients in the TAV group, who needed reintubation secondary to respiratory failure (P = 0.63). Mean ± SD hours of ventilation and intensive care unit admission was 14.05 ± 30.03 and 49.43 ± 39.12 in the BAV group and 14.77 ± 88.13 and 77.55 ± 106.43 in the TAV group (P = 0.12 and P = 0.67), respectively. Mean ± SD days of hospital stay also was not significantly different between BAV (4.03 ± 3.02) and TAV groups (5.72 ± 6.37) (P = 0.74) ( Table 2 ).
| Echocardiography outcomes
All patients in either group had echocardiography after TAVR. All TTEs were done before discharge with a mean ± SD of 2 ± 1. Patients were stratified based on valve type, and MI, age ≥70, and PAD were entered into the Cox regression analysis in both TAV and BAV groups. PAD and age ≥ 70 were recognized as the predictors of overall mortality in the BAV group only, HR = 7.3 (95%CI 1.3-46.2) and 6.1 (95%CI 1.1-34.5), respectively. There was no significant association between preoperative characteristics and overall or within group postprocedural stroke and PVL in multivariate logistic regression analysis. However, the statistical power of this finding is low due to the small sample size and low number of events.
| Univariate and multivariate analysis
| Potential confounding assessment
When examining the association of valve type (TAV vs BAV) with mortality, stroke, and PVL as a single independent variable (unadjusted) as well as in a model adjusting for age, prior MI, and aortic annular area (adjusted), no significant differences were observed (supplementary Table S1 ). 
| DISCUSSION
We found that periprocedural and mid-term outcomes of TAVR in patients with BAV are comparable to outcomes of those with TAV. Improvement of aortic valve gradient and lack of significant PVL were also comparable between the BAV and TAV groups. In this study, the majority of patients had Sievers type 0 valves with no raphe.
We found a 6.25% 30-day mortality in our BAV group and 4.2%
30-day mortality rate in our TAV group. This was not a statistically significant difference, yet the slightly higher mortality rate in BAV patients warrants further attention. Kochman et al reported the first multicenter study from Europe using early-generation valves in 28 BAV patients and observed a similar 30-day mortality (4% in the BAV group vs 7% in the TAV group). 23 Yoon et al also compared TAVR outcomes between BAV and TAV patients, and did not find any significant difference in 30-day mortality. However, the average STS score was significantly lower in the BAV group than the TAV group. 24 The most recent study by Yoon et al had less than 2% mortality at 30 days. However, they enrolled patients with lower STS scores compared to our study with no control group of patients with TAV. 12 Two other multicenter studies by Mylotte et al and Yousef et al reported similar 30-day mortality rates to our study among patients with BAV who underwent TAVR with earlier-generation valves, 5% and 8.3%, respectively. 10, 25 In a multicenter study from Europe and Canada using new-generation valves (SAPIEN 3), 30-day mortality rate was estimated as 3.9% for patients with BAV. 17 However, they only enrolled patients with BAV with no control group of patients with TAV.
In a recent multicenter study including 301 patients from Asia, Europe, Australia, and the United States, 30-day mortality rate was 4.3%, which is comparable to our results. 15 In our study, the mid-term survival rate of patients was not different between BAV and TAV groups. Kochman et al also found a comparable 1-year mortality rate in BAV (18%) and TAV (17%) groups. 23 Yousef et al and Mylotte et al also reported similar 1-year mortality rates for patients with BAV who underwent TAVR with earlygeneration valves, 17.5% and 16.9%, respectively. 10, 25 Yoon et al reported an overall mortality rate of 14.4% at 1 year in a large BAV study. They also did not find any significant difference in mortality rate between new-and old-generation valve groups, 14.8% versus 17.6%. 15 The STS risk score was not significantly different between BAV and TAV groups in our study and was even slightly higher in the BAV group. In contrast, the STS score was significantly lower in the BAV group in Yoon et al.'s study. In addition, they included BAV patients with an intermediate risk profile (mean STS risk score = 5). 24 This difference can be explained in part by our study population being derived from a single-center United States tertiary care hospital experience, as opposed to multi-institutional registry results in earlier studies. However, the consistent message remains that TAVR outcomes in patients with BAV are comparable to outcomes of those with a TAV, even in higher-risk patients.
Postprocedural stroke rate was 3.1% in the TAV group and 6.2% in the BAV group in the present study. While this did not reach statistical significance, the stroke rate is double. Due to the heavy, eccentric calcification that often is associated with BAV, there is a theoretical risk of increased embolic phenomena in BAV patients. Kochman et al did not find any strokes in patients with BAV, but three (3.57%) patients in the TAV group developed post-TAVR stroke in their multicenter study with early-generation valves. 23 Yousef et al also employed early-generation valves and reported a low post-TAVR stroke rate (2.8%) in a study from Europe and Canada. 25 In a similar study by Mylotte et al, periprocedural stoke rate was estimated as 2.2% using early generation valves. 10 Finally, in the largest study of TAVR outcomes in BAV patients, no significant difference was found in stroke rate between early-and new-generation valve groups (2.5% vs 2%). 15 The literature suggests that the stroke rate in patients with BAV
is not statistically higher and valve generation does not play a pivotal role in postoperative stroke rate. 12 Further studies should continue to carefully examine stroke rate to identify any increased risk in BAV patients.
The major concern of TAVR in patients with BAV is the development of PVL. Some suggest this may be associated with possible aortopathy in patients with BAV. 25 Alternatively, concern for increased PVL may be attributable to asymmetric annular anatomy and bulky calcific deposits. Full expansion of the TAVR prosthesis may not occur symmetrically around the aortic annulus, thus leading to small gutters as sources for PVL. Rajani et al found a 24% incidence of significant PVL (≥3+) among patients with TAV who underwent TAVR with early-generation valves. 26 In our study, PVL greater than mild was found in 2.08% of patients with TAV. The lower rate of PVL may be partly explained by employing new-generation valves in approximately 30% of our patients, as PVL incidence is reduced by SAPIEN 3 valves. 17 In BAV patients, early-generation valves resulted in moderate or severe PVL at a rate of 6-9.6%. 10 Accurate annulus sizing is extremely important in all TAVR procedures but especially so in BAV patients due to the asymmetric nature of the aortic annulus. In addition to the usual 3-d CT reconstruction software, we also use balloon valvuloplasty when there is uncertainty about valve prosthesis size. We have also adopted more widespread use of 3-d TEE with annulus area measurements to determine prosthesis size. The larger valve size among BAV patients may also explain the tendency to have more selfexpanding prostheses in the BAV group.
In a study by Yoon et al, moderate to severe PVL was detected in up to 20% of patients who underwent TAVR with an early-generation valve. 24 They later found significantly higher rates of moderate or greater than moderate PVL in BAV patients who underwent TAVR with an early-generation valve compared to those who had TAVR with a new-generation device, 14.7% versus 2.7% (P = 0.03). 12 Perlman et al did not find any patient with moderate or severe aortic regurgitation after TAVR in BAV patients using the SAPIEN 3 valve. 17 Although more than 70% of our patients in the BAV group had TAVR with an earlygeneration valve, no patient developed severe PVL and only one (3.12%) patient had moderate PVL after TAVR.
The rate of pacemaker implantation in our study was lower than a previous study that compared outcomes between BAV and TAV groups, 12.5% versus 29% (BAV) and 13.5% versus 33% (TAV), respectively. 23 The rate was 15.4% for both BAV and TAV patients in
Yoon and associates' earlier study. 24 Our practice had been to position the valve 80% within the aorta and 20% within the ventricle, and we still continue to target this ratio. But we have a uniform practice among all operators to err on the side of positioning the valve more into the aorta to avoid the atrioventricular conduction system. Mylotte et al. found a 23.2% new pacemaker implantation rate after TAVR in patients with BAV. 10 The rate was reported at 19.4% in another multicenter study by Yousef et al using earlygeneration devices. 25 Yoon et al found similar new permanent pacemaker insertion rates between early-generation (13.1%) and new-generation (16.7%) valves. 15 However, post-TAVR pacemaker implantation rate decreased to 12% with no difference between early-(8.8%) and new-generation (13.5%) valves in their most recent study (P = 0.49), 12 consistent with the finding in our current study.
Another study including 51 patients with BAV who underwent TAVR with the SAPIEN 3 valve reported a 23.5% rate of new pacemaker implantation after TAVR. 17 These results suggest that need for pacemaker implantation in patients with BAV is not higher than those with TAV and is not associated with the generation of valve, although BAV has been shown to be a risk factor for pacemaker after open AVR. 27 Our results and previous studies suggest that TAVR is an appropriate treatment option for BAV patients with AS. However, it seems that there is some overlap in patient populations in previous multicenter studies, 10, 15, 17, 25 leading to a selection bias secondary to enrollment of the same patient groups in different studies. We had 100% procedural success rate with no conversion to open-valve surgery or aortic damage, but less PVL compared to the most recent multicenter study including patients from North America, Europe, Asia, and Australia, who underwent the TAVR procedure by several interventional groups with different levels of experience. 24 Therefore, a multicenter study from the Unites States is required to include BAV patients with similar environmental and life-style factors.
| Study limitations
We acknowledge the following limitations in our study. First, this was a single-center retrospective study with a limited number of patients to perform propensity match analysis such that the two groups may not have strong statistical power due to the small sample size. Second, the study design spanned several years during which time there has been marked improvements in valve designs and fewer patients received the newest generation prostheses. While this study is lacking in data on annulus circularity, BAV patients tend to have a more irregular-shaped aortic annulus. A BAV patient with severe calcification and an extremely irregular-shaped annulus may be at risk for significant PVL and may be preferentially referred for surgical AVR. However, if left ventricular outflow tract calcium is minimal, TAVR can still be performed in BAV patients despite a more eccentric-shaped annulus.
Finally, although Sievers type 1 is the most common variant, the majority of our patients were Sievers type 0. This may limit generalizability of our results to all BAV patients. However, we did not find a significant difference in aortic root and annulus geometry between Sievers type 0 and type 1. While the primary outcome of this study was 30-day mortality, additional secondary outcomes were examined as well, and there exists the possibility of type I error inflation due to multiple hypothesis testing. Although multiple hypothesis testing is an issue of concern, the fact that only four outcomes were analyzed lessens this concern. 
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